News

OST-HER2, an investigational immunotherapy, yielded favorable overall survival outcomes ahead of an FDA meeting to consider its basis for approval.

DeLLphi-305 data show tarlatamab plus durvalumab significantly improved overall survival as first-line maintenance in extensive stage small cell lung cancer.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

U.S. alcohol-linked cancer deaths double since 1990, led by surging liver cancer; men, older adults hit hardest, with wide state-by-state gaps.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T move earlier.

The FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify eligible patients for the camizestrant regimen.

Published results from the PARADIGM study of azacitidine/venetoclax showed an event-free survival benefit and lower hemorrhage rates in acute myeloid leukemia.

ALINA trial shows adjuvant alectinib after ALK+ lung cancer surgery improves quality of life, with manageable safety and durable DFS.

AUA/SUO's 2026 NMIBC guideline amendment adds 40 statements on risk stratification, surveillance intervals, urinary biomarkers, and emerging BCG-unresponsive therapies.

The study also identified a link between early fatigue and eventual response to CAR-T.

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where pirtobrutinib fits next.

Ivonescimab extends survival and doubles PFS vs pembrolizumab in first-line PD‑L1+ metastatic NSCLC, with manageable safety.

Etentamig surpassed standard therapy in terms of response rate and progression-free survival in the phase 3 CERVINO trial for relapsed/refractory multiple myeloma.

A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling personalized risk stratification.

Daraxonrasib showed dose-dependent objective response rates of 31% to 37% in previously treated RAS-mutant NSCLC, per phase 1/2 trial data published in the New England Journal of Medicine.

During a virtual event, Eric K. Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer.

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

FDA grants breakthrough status to JBS-003 F-MISO PET imaging, aiming to personalize radiation in HPV-positive throat cancer by safely reducing dose for nonhypoxic tumors.

Phase 3 SANOVO shows savolitinib plus osimertinib extends PFS in first-line EGFR-mutant, MET-high NSCLC, hinting at OS gains.

The phase 2b VISUALIZE trial found abenacianine identified a clinically significant event in 45% of lung cancer surgeries, says Gavin M. Wright, MBBS, FRACS, PhD.

Learn how oncologists spot burnout early and cut it with smarter workflows, PTO coverage, supportive leadership, and AI-powered documentation.

The application for the selinexor combination is supported by data from the phase 3 SENTRY trial.

The OS findings follow the recent FDA approval of zanidatamab with or without tislelizumab in HER2-positive gastroesophageal cancer.

FDA aligns on IDE849 phase 3 trial in post-tarlatamab ES-SCLC, testing DLL3 ADC vs chemo, aiming for accelerated approval.

August 2026 FDA oncology updates: iberdomide, zanidatamab, and daraxonrasib win approvals as fast-track designations accelerate targeted pipelines.

A JAK inhibitor with a favorable safety profile demonstrated clinical activity in patients with chronic graft-vs-host disease.

The approval marks the first new agent specifically approved for essential thrombocythemia in the US in nearly 30 years.

ASCO's updated guideline on breast cancer follow-up recommends risk-based surveillance intensity and selective mammography rather than one-size-fits-all follow-up.